Published: 3 March 2022
Author(s): Koen C. van Son, Maarten E. Tushuizen, Adriaan G. Holleboom, Joost P.H. Drenth
Issue: April 2022
Section: Commentary

Currently the global prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be around 25% for the general adult population [1], with estimates over 50% in populations with type 2 diabetes mellitus [2]. Meta-analyses by Dulai et al. (2017) and Taylor et al. (2020) indicate that liver fibrosis in NAFLD is an independent risk factor for all-cause mortality and liver-related mortality [3,4]. This underscores the need to stage NAFLD in order to detect patients with advanced stage fibrosis or cirrhosis


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.